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1748-6815/ª 2017 British Association of PSummary AlloDerm RTU and AlloMaxTM are two acellular dermal matrices (ADMs) used in
implant-based breast reconstruction. In this study, we examined whether different processing
methods for the ADMs lead to a disparity in histologic, clinical, and financial outcomes after
breast reconstruction. Thirty patients undergoing implant-based breast reconstruction were
randomized into AlloMax or AlloDerm arms (nZ 15, each). ADM was placed at the time of im-
mediate reconstruction. Patients were evaluated for complications on postoperative days 7,
14, and 30. During implant exchange, ADM biopsies were taken and compared histologically
for vascular and cellular infiltration. Patient satisfaction was evaluated using the BRECON-31
questionnaire 1 year after implant exchange. A cost analysis was performed comparing the
two ADMs. Patient demographics and complication rates were similar between the two groups
(p > 0.05). Histologically, vessel density and fibroblast/inflammatory cell infiltrate were
greater on the dermal side than on the implant side (p < 0.01) in both ADMs, suggesting greater
vascular and cellular in-growth from the dermal side. Vessel density in the middle portion of
the Allomax biopsies was significantly higher than the same site in the Alloderm biopsies
(p < 0.05). The extent of fibroblast/inflammatory cell infiltration was similar in both arms
(p > 0.05). The BRECON-31 satisfaction questionnaire yielded similar responses across all met-
rics between the two study arms. The negotiated price was slightly different when comparingat the Annual Meeting of California Society of Plastic Surgeons, SundayMay 24, 2015, Monterey Bay, CA.
f California e Davis Medical Center, Division of Plastic Surgery, Cypress Building, 2221 Stockton Blvd.,
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10.1016/j.bjps.2017.02.024the two ADMs, with no significant difference in ADM reimbursement. In this study, AlloDerm
RTU and AlloMax were successfully used for implant-based breast reconstruction with compa-
rable outcomes.
ª 2017 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Else-
vier Ltd. All rights reserved.Introduction
Implant-based breast reconstruction accounts for 73% of
the over 102,000 breast reconstructive procedures per-
formed annually in the United States.1 Unfortunately,
there are several esthetic disadvantages associated with
breast restoration using prosthetic implants. These include
visible rippling, capsular contracture, implant malposi-
tion, bottoming out, and implant exposure. A majority of
these complications are due to tissue thinning from the
expansion process, inadequate filling or incorrect place-
ment of the implant, or over generous formation of the
breast pocket.2 Placement of an appropriately sized piece
of acellular dermal matrix (ADM) between the implant and
the skin can augment the skin thickness and act as a sling
to support the implant, reducing the risk of complications
(Figure 1).he placement of ADM between
on of the ADM to the recipient
inchcliff KM, et al., Comparison
mized trial, Journal of Plastic,Since ADM was first used in breast reconstruction in
2005,3 a plethora of ADMs have become available on the
market. However, the choice of which ADM to use can seem
distressingly random. Most ADMs are derived from cadaveric
tissues that are decellularized and often terminally steril-
ized using different proprietary techniques that are then
performed to different degrees of intensity.16 This results in
different storage requirements, shelf lives, intraoperative
preparation methods, and costs. Furthermore, pharma-
ceutical companies may stress these differences in sterility
to show that their products are safer than those of their
competitors.
Currently, surgical practice is based more on product
availability or anecdotal experience than on scientific data.
While more recent studies have begun to objectively study
the difference in outcomes between ADM products,4e9
randomized prospective studies with supporting histologicthe skin and the breast implant to provide an additional layer
tissue occurs with fibroblast and vessel ingrowth.
of two cadaveric acellular dermal matrices for immediate breast
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products in use at University of California Davis, Alloderm
Ready To Use (RTU) (LifeCell Corp., Branchburg, NJ) and
Allomax (Bard Davol Inc., Cranston, RI) (Table 1), in a
single-blinded, prospective randomized controlled trial,
focusing on clinical outcomes, patient satisfaction, and
histologic differences.Materials/methods
Study design and patient selection
The study was approved by the University of California
Davis Institutional Review Board (protocol # 415153-2).
For our power analysis, we set a Z 0.05 and b
(power) Z 0.08. The Jansen et al. review of Alloderm
use in breast reconstruction showed an infection
rate of 0e11%.10 When excluding direct-to-implant re-
constructions and papers with fewer than 11 total pa-
tients, the average infection rate in these studies was
3.38  2.30. Less has been published on Allomax, a rela-
tively newer product, but the literature has estimated the
infection rate at 1%.11 On the basis of this data, we
determined that 15 patients would need to be enrolled in
each study arm.
The criteria for enrollment included any patients
over 18 years of age or older seeking a two-stage expander
to implant-based breast reconstruction. Patients who
were enrolled were then randomized in a 1:1 ratio to
AlloMax or AlloDerm RTU arms using a blocked randomi-
zation scheme. Randomization was performed in two
strata, one consisting of subjects who were nonsmokers
and nondiabetic and the other consisting of smokers and/
or diabetics.Table 1 Product specifications for Alloderm RTU and
Allomax.
Alloderm RTU Allomax
Decellularization
process
Sodium chloride þ Sodium
deoxycholate þ freeze
drying
Tutoplast
process
Storage Room temperature Room
temperature
Rehydration 2 min 5 min
Directionality Basement membrane
and dermal side
Noneb
Shelf life 2e5 years 5 years
Contraindications Allergy to Polysorbate 20
or any of the antibiotics
used in processing of the
tissue as listed on the
outer package
SALa 103 106
a SALZ Sterility Assurance Level: Only Allomax meets the
Food and Drug Administration’s standards for sterility, which
requires a SAL of 106 or less.
b A newer product, marketed specifically for bilateral breast
reconstruction, is sided.
Please cite this article in press as: Hinchcliff KM, et al., Comparison
reconstruction: A prospective randomized trial, Journal of Plastic,
10.1016/j.bjps.2017.02.024In the first operation, a tissue expander and ADM were
placed. Patients were examined at postoperative 7, 14, and
30 days for drain care and wound evaluation (Table 2).
Drains were left in place until output was <20 mL/day on
two consecutive days. Expansion started on average 30 days
postoperatively (Table 2). Patients were monitored in clinic
throughout the expansion process and for 1 year after
implant placement (Table 2). Our primary clinical outcome
measure was the complication rate, including the need for
expander removal, skin necrosis, infection, seroma, he-
matoma, and skin necrosis. Patient satisfaction was evalu-
ated 1 year after implant exchange using the BRECON-31
questionnaire, which is a validated breast reconstruction
satisfaction questionnaire.12,13
Surgical technique
All procedures were performed by a single academic sur-
geon using a standardized operative technique. During the
first stage of reconstruction, subpectoral pockets were
created. The wounds were irrigated with a triple antibiotic
solution containing 50,000 units Bacitracin (Pfizer, New
York, NY), 1 g of Cefazolin (GlaxoSmithKline, Middlesex,
UK), and 80 mg Gentamicin (Baxter, Mississauga, ON) in 1 L
of normal saline. The chosen ADM was then prepared ac-
cording to the manufacturer’s instructions, cut to size, and
secured to the inframammary fold. The tissue expanders
(Mentor, Santa Barbara, CA) were then placed in the sub-
pectoral pocket and inflated to fill the dead space. Two
drains were placed, one in the subpectoral pocket and
another in the subcutaneous pocket, and the skin flaps
were closed over the pectoralis muscle in a standard
fashion.
During the second stage of the reconstruction, the prior
mastectomy scar was reopened and the expander was
removed. Depending on the level of capsule formation, a
capsulotomy or capsulectomy was performed. For the first
10 study patients, a 1  1 cm biopsy of the ADM was taken
from the matrix edge and transferred to the laboratory for
further histological analysis. After appropriate sizing, the
implant was placed in the pocket using an atraumatic, no
touch technique, and the wounds were closed in the stan-
dard fashion.Table 2 Timetable for the procedures performed during
the study.
Procedure Postoperative day (POD)
ADMa and TEb placement POD 0
Clinic follow-up visit POD 7
Clinic follow-up visit POD 14
Clinic follow-up visit & start
of expansion
POD 30
Implant exchange and ADM
biopsyc
variable
Clinic follow-up visit POD 1 year
a ADM Z acellular dermal matrix.
b TE Z tissue expander.
c Definitive reconstruction was delayed at least 4 weeks after
completion of chemotherapy and 12 months after radiotherapy.
of two cadaveric acellular dermal matrices for immediate breast
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The biopsy specimens were processed and embedded in
paraffin blocks. The embedded samples were cut into
10 mm sections, and two slides per specimen were stained
with hematoxylin-eosin (HE). Stained slides were examined
under 20magnification, and five pictures were taken from
each of the dermal, middle, and implant portions of the
ADM totaling 15 pictures per section (Figure 2). Blood ves-
sels in each image were counted manually using ImageJ
software (Rasband, W.S., ImageJ, U. S. National Institutes
of Health, Bethesda, Maryland, USA, http://imagej.nih.
gov/ij/, 1997e2016). With two sections per slide, we
could obtain 20 different vessel/high power field (HPF)
counts for each of the upper, middle, and lower rows in
each ADM biopsy specimen.
To further assess vascular ingrowth, von Willebrand
Factor (vWF) immunofluorescence (IF) staining was
performed. In addition, fibroblast and macrophage
infiltrations in the ADM biopsies were evaluated by anti-
fibroblast and CD68 IF staining, respectively. Briefly, slides
were incubated with the primary antibodies for vWF
(Abcam, Ab6994, Cambridge, MA), fibroblast (EMD Milli-
pore, CBL271, Billerica, MA), and CD68 (Santa Cruz
Biotechnology Inc., sc-7082, Santa Cruz, CA) for 1 h at
room temperature. The primary antibodies were tagged
with Alexa Fluor 488 (AF488)-labeled anti-goat, anti-
mouse, and anti-rabbit IgG (Invitrogen, Eugene, OR).
The nuclei were counterstained with 40,6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories, Burlingame,
CA), and the images were captured under a fluorescence
microscope. The areas with positive fluorescence were
quantified using ImageJ software by selecting the stainedFigure 2 The HE-stained ADM sections were divided into three r
each row under the microscope. Microbar 100 mm.
Please cite this article in press as: Hinchcliff KM, et al., Comparison
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10.1016/j.bjps.2017.02.024areas with the threshold function and then quantifying
these areas with the measure function.
Cost analysis
We collected information on supply charges from Bard
Davol Inc. or LifeCell Corp. Hospital charges to insurance
companies and insurance payouts were obtained from the
University of California Davis Medical Center Billing
Department. These payments were tracked using the CPT
code 15777, which applies specifically for the placement of
a biologic implant such as ADM.
Statistical analysis
Statistical analysis was performed using VassarStats: Web-
page for Statistical Computation (http://vassarstats.net/).
All comparisons were run using either the two-tailed t-test
or one-way ANOVA for comparisons of multiple samples, or
n1 two proportion test for binary values. A p value < 0.05
was considered statistically significant.
Results
Clinical results
Patients were followed for a minimum of 1 year after
implant exchange operation. The demographics of two
study arms were roughly equivalent (Table 3). Operative
demographics were also similar between the study arms
(p < 0.05) (Table 4). Two patients in the Alloderm arm
transferred care to another institution midway throughows as dermal, middle, and implant. Pictures were taken from
of two cadaveric acellular dermal matrices for immediate breast
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Table 4 Operative demographics.
AlloDerm RTU, n (%)a AlloMax, n (%)a
Unilateral 5 (20) 7 (46.7)
Bilateral 10 (40) 8 (53.3)
Initial expander
fill
123.08  64.06 mL 106.08  46.09 mL
Drain days
Drain 1 6.8  2.6 7.7  3.9
Drain 2 17  5.3 15.2  3.4
Expansion timeb 249  137.5 243  101.2
Total subjects 15 15
a n Z patient number.
b The average expansion time for those undergoing post-
operative chemotherapy or radiotherapy was 260 days.
Table 3 Patient demographics.
AlloDerm RTU, n (%)a AlloMax, n (%)a
Age (range) 49 (25e63) 51 (31e63)
BMI 25.4 (20.3e33.1) 25.9 (21.5e30.8)
Pre-op RT 2 (13.3) 2 (13.3)
RT during
expansion
3 (20) 2 (13.3)
Diabetes 2 (13.3) 1 (6.7)
Smoking 1 (6.7) 1 (6.7)
Total subjects 15 15
a n Z patient number, RT Z radiotherapy, BMI Z body mass
index.
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each group.
Major 30-day complications were defined as those
requiring a return to the operating room. The rate of major
complications in the Alloderm arm was 8.0% vs. 4.3% in the
Allomax arm. Overall, there was no significant difference
between the groups in terms of major 30-day complications
(p > 0.05) (Table 5). The rate of minor complications on
postoperative day 30 was 0% and 13.0% in Alloderm and
Allomax arms, respectively (p > 0.05). For any 30-day
complication, the rate was 8.0% vs 17.4% in the Alloderm
vs. Allomax arms (p > 0.05) (Table 5).
There were no major complications in the Alloderm arm
after implant exchange operation (Table 5). One patient in
the Allomax arm had a grade IV capsular contracture,
requiring capsulectomy, and another patient with a history
of radiotherapy to the area had implant exposure requiring
implant removal (Table 5). Of note, the grade IV contrac-
ture patient did have a history of intrinsic scarring but had
refused flap reconstruction. She developed this contraction
despite a complete capsulectomy at time of implant ex-
change and prophylactic Montelukast.
The difference between major complication rates after
implant exchange (0% in Alloderm vs. 8.9% in Allomax arms)
was not significant (p > 0.05). The rates of any major
complication throughout the complete reconstructive
course (8.0% in Alloderm vs. 13% in Allomax), expander loss
(4.0% Alloderm vs. 8.7% Allomax), or other complicationsPlease cite this article in press as: Hinchcliff KM, et al., Comparison
reconstruction: A prospective randomized trial, Journal of Plastic,
10.1016/j.bjps.2017.02.024(8.0% Alloderm, vs. 26.1% in Allomax) were not statistically
significant (p > 0.05).
One year after permanent implant placement, patients
were asked to fill out the BRECON-31 satisfaction ques-
tionnaire. We had a 43.8% response rate to this question-
naire, with patient responses being similar across all
metrics.
No statistically significant difference was observed be-
tween reimbursement for AllodermRTU and Allomax. The
negotiated price of a 6  16 cm sheet of Allomax was 12.4%
less than the negotiated price for Alloderm RTU at our
institution. Both were billed under the CPT code 15777,
and the amount billed to the insurance company was
either $679.00 or $723.00, regardless of the type of ADM
used. Average reimbursement for one sheet of Allo-
dermRTU was $298.6  203.6, vs. $211.2  133.4 for a
similarly sized piece of AlloMax (p > 0.05). Because of the
diversity of insurance companies in our patient population,
we could not draw a definitive conclusion whether ADMs
were reimbursed differently by the same insurance com-
pany. However, the data that we have suggest that there is
none.Histologic results
The mean vessel number/HPF in the Allomax specimens
was 6.50  4.9 at the dermal portion, 2.84  3.3 at the
middle, and 1.36  2.09 at the implant portion. The
difference between these portions was statistically sig-
nificant (p < 0.01) (Figure 4). Comparable values in the
Alloderm arm were 5.37  2.8, 1.76  2.4, and
1.06  1.8, respectively. The difference between the
portions was again significant (p < 0.01) except for the
middle vs. implant portion comparison, which trended
toward but did not achieve significance (p Z 0.08). On
the basis of these findings, there was statistically signif-
icant evidence of vessel in-growth from the dermal sur-
face of both ADMs.
When comparing Alloderm to Allomax, there were
significantly more vessels in the middle portion of Allomax
(p < 0.05) with a trend toward the significance at the
dermal portion (p Z 0.08). The difference between the
vessel numbers in implant portions was not significant
(p > 0.05) (Figure 4).
Both Alloderm and Allomax specimens had significantly
more fibroblasts at the dermal portion (p < 0.01). The
proportion of positively stained areas in dermal, middle,
and implant portions was 4.37  3.9%, 1.15  1.5%, and
1.63  1.5% of the whole surface area of HPF (% HPF) in the
Allomax arm and 3.51  2.9%, 0.91  1.2%, and
0.91  1.03% HPF in the Alloderm arm. While the Allomax
arm had consistently higher amount of fibroblasts than the
Alloderm arm, none of these differences achieved signifi-
cance (p < 0.05) (Figure 5).
The proportion of CD68-stained areas also decreased
from dermal toward the implant side of the ADM in both the
Alloderm and Allomax specimens, although the difference
between the portions did not achieve significance
(p > 0.05). CD68-positive areas were 3.81  3.6%,
3.03  3.5%, and 2.24  2.2% HPF for the dermal, middle,
and implant side in the Alloderm arm and 3.79  2.3%,of two cadaveric acellular dermal matrices for immediate breast
Reconstructive & Aesthetic Surgery (2017), http://dx.doi.org/
Figure 3 The figure shows preoperative and postoperative pictures of representative patients from Alloderm and Allomax groups.
Table 5 Clinical complications.
Postoperative 30 day
Alloderm
RTU, n (%)a
Allomax,
n (%)a
Major
TEb exposure 1 (4) 1 (4.3)
Hematoma 1 (4)
Minor
Wound necrosis e 1 (4.3)
Seroma e 1 (4.3)
Cellulitis e 1 (4.3)
Postexchange
Major
Implant exposure, e 1 (4.3)
Grade IV contracture e 1 (4.3)
Minor e e
Total 2 (8) 6 (26.1)
a n Z number of breasts.
b TE Z tissue expander.
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respectively. No significant difference was observed be-
tween the two study arms (Figure 6).
Discussion
Several papers have been published in the last 5 years
comparing different ADMs from a histologic or a clinical
outcomes perspective, many sponsored by industry. Studies
focusing on histology tried to determine the clinical impli-
cations using only the histological data while clinical in-
vestigations did not study the underlying histology. Our
study seeks to address this gap in the literature by simul-
taneously addressing both issues in detail with a prospec-
tive, randomized study.
Histologic studies of ADM implantation in rat and porcine
models have consistently shown vascular ingrowth and in-
flammatory cell penetration into the ADM, in both sterile
and aseptic matrices.8,14,15 However, these studies have
not been consistent with regard to which ADM is associated
with greater cellular and vascular ingrowth. In our study,
we found statistically significant evidence of vessel
ingrowth from the dermal side of the matrix and found
evidence of greater ingrowth into the Allomax product,
with more vessels present per HPF in the middle of the ADM
than the same site in the Alloderm product. In addition, we
found evidence of fibroblast infiltration from the dermal
side of the matrix in both ADMs, but no significant differ-
ence was found between products. One potential reason
that these products acted more similarly in our study than
in previous animal studies14 could be because we used
Alloderm RTU, which is now sterilized, unlike the earlier
Alloderm RTM product. The demographic differencesPlease cite this article in press as: Hinchcliff KM, et al., Comparison
reconstruction: A prospective randomized trial, Journal of Plastic,
10.1016/j.bjps.2017.02.024between study arms in our study (e.g., diabetes, radio-
therapy, smoking, and obesity) might also have acted as a
confounding factor to account for the differences in
incorporation on a histological level. However, the pro-
spective randomized nature of our study should have
minimized such confounding.
Fundamentally, the question that surgeons want to
answer is whether the differences in processing between
ADM products lead to any difference in clinical outcomes.
Alloderm has been on the market for a long time, and asof two cadaveric acellular dermal matrices for immediate breast
Reconstructive & Aesthetic Surgery (2017), http://dx.doi.org/
Figure 4 (A) Vascular density (average number of vessels/high power field) calculation in each row of ADMs was performed
depending on HE staining. Black arrowheads indicate the vessels. Microbar 100 mm. (B) The presence of vessels was also confirmed
with vWF IF staining. White asterisks (*) are in the vessel lumens. Microbar 200 mm. (C) The graph shows the comparison of vascular
density of the rows between the groups. *p < 0.01, jp < 0.05.
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frequently compared against. Retrospective studies com-
paring Alloderm to Surgimend,4 Strattice,7 FlexHD,17
and DermaMatrix9 have failed to show a significant dif-
ference between the clinical outcomes of these ADM
products. However, it is important to note that the Allo-
derm product studied in these reviews is the earlier RTM
product. Studies comparing Alloderm RTM to the terminally
sterilized RTU product have shown the risk of infection with
Alloderm RTU use is lower,18 but the risk of seroma for-
mation is significantly higher,19 differences that may be
attributable to the changes in preparation and sterilization.
The only other prospective trial to date, comparing Allo-
derm vs. Dermamatrix, found no significant difference in
complication rates between the two products but did see a
significantly shorter number of expansion days in the Allo-
derm group vs. the DermaMatrix group (70 vs. 42 days,
p < 0.001).6 The authors attributed this difference to
anecdotal experience that Alloderm is more pliable; how-
ever, no histological or objective pliability data accompa-
nied this conclusion.Please cite this article in press as: Hinchcliff KM, et al., Comparison
reconstruction: A prospective randomized trial, Journal of Plastic,
10.1016/j.bjps.2017.02.024Our 30-day complication rates of 4.3% and 8% for
major complications and 26.1% and 8% for any compli-
cation rate are consistent with the published data and
compare favorably to other randomized controlled tri-
als.6 Also in keeping with the literature, our rate of
comorbidities such as smoking, diabetes, or prior radio-
therapy were seen at a higher rate in patients who had
complications across both arms (37.5% of patients who
developed a complication had a comorbidity vs. 20.1% in
the study population).
Our drain data were also similar to the published rates
and were not significantly different between study arms.
One notable data point in our study was that our expansion
time was much longer than that in other studies, even ac-
counting for the difference between patients requiring
postoperative chemotherapy or radiotherapy. Postulated
reasons for this include low intraoperative expander fill
(just over 100 mL on average for both arms) and that pa-
tients were given the option to expand more slowly (every
other week or less) to decrease the discomfort of expansion
and the risk of flap necrosis.of two cadaveric acellular dermal matrices for immediate breast
Reconstructive & Aesthetic Surgery (2017), http://dx.doi.org/
Figure 5 (A) Anti-fibroblast staining revealed the extent of
tissue invasion into ADMs. Microbar 100 mm. (B) Fibroblast
staining was similar between the study arms. Fibroblast infil-
tration was significantly higher in the upper rows in both ADMs
in comparison to middle and lower rows. *p < 0.01, jp < 0.05.
Figure 6 (A) CD68 IF staining was performed to evaluate
the extent of inflammatory reaction toward the ADMs. White
arrowheads indicate the CD68-positive inflammatory cells.
Microbar 100 mm. (B) CD68 staining was similar between the
study arms (p < 0.05).
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outcomes between the two ADMs suggests that cost
could be used as a determining factor in deciding what
ADM to use and surgeon preference with the different
handling properties. While there has been an anecdotal
discussion at our institution about lower reimbursement
for non-Alloderm products, our data found that this was
not the case. Because the University of California Health
System uses the same billing code for both Alloderm and
Allomax, no significant difference was observed in
reimbursement between arms. In addition, we sub-
divided our cost data by an insurance carrier to deter-
mine if the same carrier reimbursed differently for
Alloderm vs. Allomax. Because of the diversity of in-
surance carriers, we could make two such comparisons
(Medicare and Blue Shield). Making this comparison,
there did not appear to be a difference in reimburse-
ment between ADM types.
Our study provides a high level of evidence but was
limited by its power. While the previous literature sug-
gested that a sample size of 15 patients per arm would be
sufficient to see a clinical difference, we did not consider
that the newer Alloderm RTU might behave similarly to
Allomax, perhaps because of its increased sterility.Please cite this article in press as: Hinchcliff KM, et al., Comparison
reconstruction: A prospective randomized trial, Journal of Plastic,
10.1016/j.bjps.2017.02.024Conclusion
This study demonstrates an acceptable safety and outcome
profile with both Alloderm RTU and Allomax use in imme-
diate breast reconstruction. In this prospective randomized
trial, differences in processing and sterilization did not
equate to large differences in histologic and clinical out-
comes, although there was greater vessel ingrowth seen
into the Allomax product and a trend toward more minor
complications in the AlloMax arm. In the absence of
objective clinical differences, we believe that surgeon
preference and cost should be considered when deciding
which ADM to use for breast reconstruction.Conflict of interest or funding
None.Acknowledgments
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